Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: Placebo
- Registration Number
- NCT02273375
- Lead Sponsor
- Canadian Cancer Trials Group
- Brief Summary
The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1415
-
Histologically confirmed diagnosis of primary non-small cell carcinoma of the lung. according to WHO Classification of Tumours (WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. WHO/IARC Classification of Tumours, 4th Edition, Volume 7). Patients with large-cell neuroendocrine carcinomas are not eligible.
-
Patients must be classified post-operatively as Stage IB (≥ 4cm in the longest diameter), II or IIIA on the basis of pathologic criteria. Note: Although T3N2M0 tumours have been reclassified to stage IIIB in the 8th edition of the IASLC staging system, these patients remain eligible (as stage IIIA under the 7th edition criteria).
- Complete surgical resection of the primary NSCLC is also mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour. Resection may be accomplished by open or VATS techniques
Note: Patients with synchronous primary tumours will not be eligible due to the potential uncertainty regarding their appropriate PD-L1 status.
Prior Systemic Therapy:
- Pre-operative (neo-adjuvant) platinum based or other chemotherapy is not permissible.
- Patients may have received prior post-operative platinum based chemotherapy as per standard of care.
- No prior anticancer therapy for treatment of NSCLC other than standard post-operative adjuvant chemotherapy is permissible.
Radiation:
• Patients with N2 disease only who receive adjuvant post-operative radiation therapy are eligible provided they meet the protocol specified timing criteria for surgery, adjuvant chemotherapy and randomization. Pre-operative radiation therapy is not permissible.
- The patient must have an ECOG performance status of 0, 1.
- Hematology: . Absolute neutrophil count ≥ 1.5 x 109/L or ≥ 1,500/µl Platelets ≥ 100 x 109/L or ≥ 100,000/µl
- Biochemistry:
Total bilirubin* ≤ institutional upper limit of normal Alkaline phosphatase ≤ 2.5 x institutional upper limit of normal AST(SGOT) and ALT(SGPT) ≤ 2.5 x institutional upper limit of normal Creatinine Clearance ≥ 40 ml/min
* excluding Gilbert's syndrome
Creatinine clearance to be measured directly by 24 hour urine sampling or as calculated by Cockcroft Formula:
Females: GFR = 1.04 x (140-age) x weight in kg serum creatinine in μmol/L Males: GFR = 1.23 x (140-age) x weight in kg serum creatinine in μmol/L
- Patient able and willing to complete the QoL, economics and other questionnaires. The baseline assessment must already have been completed within required timelines prior to randomization. Inability (illiteracy, loss of sight, or other equivalent reason) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible
- Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate
- Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up
- Protocol treatment is to begin within 2 working days of patient randomization
-
Patients with a history of other malignancies, except:
- adequately treated non-melanoma skin cancer,
- curatively treated in-situ cancer, or
- other malignancies curatively treated with no evidence of disease for ≥ 5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy.
-
A combination of small cell and non-small cell lung cancer, pulmonary carcinoid tumour or large-cell neuroendocrine carcinoma (LCNEC).
-
History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. NOTE: patients with Grave's disease and/or psoriasis not requiring systemic therapy within the last two years from randomization and patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement are not excluded.
-
History of primary immunodeficiency, history of allogenic organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 28 days of randomization* or a prior history of severe (grade 3 or 4) immune mediated toxicity from other immune therapy.
-
Live attenuated vaccination administered within 30 days prior to randomization.
-
History of hypersensitivity to MEDI4736 or any excipient.
-
Patients who have experienced untreated and/or uncontrolled cardiovascular conditions and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart failure, myocardial infarction within the previous year or cardiac ventricular arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular conduction defects). Patients with a significant cardiac history, even if controlled, must have a LVEF > 50% within 12 weeks prior to randomization.
-
Concurrent treatment with other investigational drugs or anti-cancer therapy.
-
Patients with active or uncontrolled infections or with serious illnesses or medical conditions which would not permit the patient to be managed according to the protocol. This includes but is not limited to:
- known clinical diagnosis of tuberculosis;
- known active hepatitis B infection (positive HBV surface antigen (HBsAg)). Patients with a past or resolved hepatitis B infection (defined as presence of hepatitis B core antibody (anti-HBc) and absence of HBSAg) are eligible;
- known active hepatitis C infection. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA;
- known human immunodeficiency virus infection (positive HIV antibodies).
- known pneumonitis or pulmonary fibrosis with clinically significant impairment of pulmonary function
-
Pregnant or lactating women. Women of childbearing potential must have a urine pregnancy test proven negative within 14 days prior to randomization. Men and women of child-bearing potential must agree to use adequate contraception.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description MEDI4736 MEDI4736 MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier. Placebo Placebo PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier
- Primary Outcome Measures
Name Time Method Compare Disease free survival (DFS) for patients with NSCLC that is PD-L1 expression TC ≥ 25% and patients without common activating EGFR mutations or ALK gene rearrangements 6.7 years
- Secondary Outcome Measures
Name Time Method Disease-free survival in the remaining 5 patient sub-populations defined by PD-L1 expression levels and EGFR/ALK status 8 years (PD-L1 TC ≥ 1% and patients without common activating EGFR mutations or ALK gene rearrangements; all patients without common activating EGFR mutations or ALK gene rearrangements; all PD-L1 TC ≥ 25%; all PD-L1 TC ≥ 1%; all randomized patients)
Evaluate the nature, severity and frequency of adverse effects and tolerability of MEDI4736 every 6 months All patients who receive at least one dose of MEDI4376/placebo will be included in the safety analysis. Descriptive summary tables will be presented on safety parameters by treatment arm. There will be safety monitoring by the CCTG Data Safety Monitoring Committee (DSMC) every 6 months
Determine the incremental cost effectiveness and cost utility ratios for MEDI4736 8 years Evaluation of changes in plasma/serum cytokines and other blood and tissue based biomarkers after treatment with MEDI4736 and at disease event 8 years Compare Lung cancer specific survival for patients in the six patient sub-populations defined by PD-L1 expression levels and EGFR/ALK status 8 years Evaluate the Quality of life in the six patient sub-populations defined by PD-L1 expression levels and EGFR/ALK status 8 years The quality of life (QoL) of patients will be assessed using EORTC QLQ-C30 and the lung cancer module (QLQ-LC13) incorporated.
Determine survival benefits participants judge necessary to make adjuvant immunotherapy worthwhile 8 years Explore polymorphisms that may be associated with outcomes Baseline only Compare overall survival (OS) for patients in the six patient sub-populations defined by PD-L1 expression levels and EGFR/ALK status 8 years Evaluate the predictive/prognostic significance of PD-L1 expression 8 years
Trial Locations
- Locations (270)
University Health Network
🇨🇦Toronto, Ontario, Canada
Hopital Avicenne
🇫🇷Bobigny, France
Paris - Institut Curie
🇫🇷Paris Cedex 5, France
Hospital Germans Trias i Pujol
🇪🇸Badalona, Barcelona, Spain
QEII Health Sciences Centre
🇨🇦Halifax, Nova Scotia, Canada
Allan Blair Cancer Centre
🇨🇦Regina, Saskatchewan, Canada
Hyogo College of Medicine
🇯🇵Nishinomiya-shi, Hyogo, Japan
National Hospital Organization Kure Medical Center
🇯🇵Kure, Hiroshima, Japan
Kansai Medical University Hospital
🇯🇵Hirakata, Osaka, Japan
Osaka City General Hospital
🇯🇵Osaka, Japan
Oncological Institute "Ion Chiricuta"
🇷🇴Cluj-Napoca, Romania
National Hospital Organization Kyushu Medical Center
🇯🇵Fukuoka, Japan
Kanagawa Cancer Center
🇯🇵Yokohama City, Japan
Osaka International Cancer Institute
🇯🇵Osaka, Japan
Oncology Institute Bucharest
🇷🇴Bucharest, Romania
National University Hospital
🇸🇬Singapore, Singapore
Chang-Gung Memorial Hospital - Linkou
🇨🇳Taoyuan, Taiwan
E-Da Hospital
🇨🇳Kaohsiung City, Taiwan
Vinnytsia Regional Clinical Oncology Dispensary
🇺🇦Vinnitsia, Ukraine
Samodzielny Publiczny Szpital Specjalistyczny
🇵🇱Zakopane, Poland
Conformal Med Terra HIFU
🇷🇴Bucharest, Romania
CHU - Angers
🇫🇷Angers, France
Hospital Vall d Hebron
🇪🇸Barcelona, Spain
BCCA - Fraser Valley Cancer Centre
🇨🇦Surrey, British Columbia, Canada
MHAT Serdika - Medical Oncology Clinic
🇧🇬Sofia, Bulgaria
Medical Centre Synexus
🇧🇬Sofia, Bulgaria
MHAT Nadezhda Hospital
🇧🇬Sofia, Bulgaria
Tom Baker Cancer Centre
🇨🇦Calgary, Alberta, Canada
CancerCare Manitoba
🇨🇦Winnipeg, Manitoba, Canada
Instituto Nacional de Cancer (INCA)
🇧🇷Rio de Janeiro, Brazil
The Jewish General Hospital
🇨🇦Montreal, Quebec, Canada
Lille - Hopital Calmette
🇫🇷Lille, France
Centre Hospitalier les Chanaux
🇫🇷Macon, France
Hopital Europeen
🇫🇷Marseille, France
Centre Hospitalier General de Pau
🇫🇷Pau, France
Thunder Bay Regional Health Sciences Centre/Thunder
🇨🇦Thunder Bay, Ontario, Canada
Hopital Albert Michallon
🇫🇷Grenoble, Cedex 9, France
Centre Antoine Lacassagne - Nice
🇫🇷Nice, France
Versailles - CH Andre Mignot
🇫🇷Le Chesnay, France
Centre Hospitalier du Mans
🇫🇷Le Mans, France
Nouvel Hopital Civil Hopitaux
🇫🇷Strasbourg, France
Thonon-les-Bains - Hopital Georges Pianta
🇫🇷Thonon Les Bains, France
CHITS Toulon Sainte Musse
🇫🇷Toulon, France
Centre Hospitalier - Avignon
🇫🇷Avignon, France
Institut Sainte Catherine
🇫🇷Avignon, France
Centre Hospitalier Intercommunal de Creteil
🇫🇷Creteil, France
Semmelweis University Pulmonology Department
🇭🇺Budapest, Hungary
Hopital Saint Louis
🇫🇷Paris, France
Oncologia Medica IRCCS Arcispedale Maria
🇮🇹Reggio Emilia, RE, Italy
Intstituto Scientifico Romangnolo
🇮🇹Meldola, Italy
Centre Hospitalier Rene Dubos
🇫🇷Pontoise, France
Paris - HEGP
🇫🇷Paris, France
Suresnes - Foch
🇫🇷Suresnes, France
Ospedale S. Paolo - U.O. di Oncologia Medica
🇮🇹Milano, MI, Italy
Uijeongbu ST Marys Hospital
🇰🇷Gyeonggi-do, Korea, Republic of
Istituti Fisioterapici Ospitalieri IFO Istituto
🇮🇹Rome, RM, Italy
A.O. Busto Arsizio - P.O. Saronno
🇮🇹Saronno, VA, Italy
Spital Lotus SRL
🇷🇴Ploiesti, Romania
Hospital Insular de Gran Canaria
🇪🇸Las Palmas, Gran Canaria, Spain
Centrul de Oncologie Sf Nectarie
🇷🇴Craiova, Romania
Chang-Gung Memorial Hospital - Chiayi
🇨🇳Chiayi City, Taiwan
Hospital Mutua de Terrassa
🇪🇸Terrassa, Barcelona, Spain
Hospital Puerta de Hierro
🇪🇸Madrid, Spain
SC Oncolab SRL
🇷🇴Craiova, Romania
Hospital General de Alicante
🇪🇸Alicante, Spain
Free University Hospital
🇳🇱Amsterdam, Netherlands
Universitair medisch centrum Nijmegen st Radboud
🇳🇱Nijmegen, Gelderland, Netherlands
Hospital de la Santa Creu i Sant Pau
🇪🇸Barcelona, Spain
Mackay Memorial Hospital
🇨🇳Taipei, Taiwan
Hospital Duran i Reynals
🇪🇸Barcelona, Spain
Hospital Teresa Herrera
🇪🇸Coruna, Spain
Taipei Medical University - Shuang Ho Hospital
🇨🇳New Taipei City, Taiwan
Hospital Universitario la Princesa
🇪🇸Madrid, Spain
Regional Oncology Center
🇺🇦Sumy, Ukraine
Veterans General Hospital - Taipei
🇨🇳Taipei, Taiwan
Tri-Service General Hospital
🇨🇳Taipei, Taiwan
The Second Affiliated Hosp of Shantou Medical Colleg
🇨🇳Shantou, Guangdong, China
The First People Hospital of Yueyang
🇨🇳Yueyang, Hunan, China
The Affiliated Hospital Of Xuzhou Medical College
🇨🇳Xuzhou, Jiangsu, China
Xuzhou Central Hospital
🇨🇳Xuzhou, Jiangsu, China
Shandong Cancer Hospital
🇨🇳Jinan, Shandong, China
Yunnan Provincial Cancer Hospital
🇨🇳Kunming, Yunnan, China
Zhongshan Hospital Fudan University
🇨🇳Shanghai, Shanghai, China
St John of God Subiaco
🇦🇺Subiaco, Western Australia, Australia
Liga Norte Riograndense Contra o Cancer
🇧🇷Natal, Rio Grande Do Norte, Brazil
Sir Charles Gairdner Hospital
🇦🇺Perth, Western Australia, Australia
USC Norris/Comprehensive Cancer Centre
🇺🇸Los Angeles, California, United States
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
AOU Ospedali Riuniti Umberto I
🇮🇹Torrette, AN, Italy
Azienda Ospedaliera San Giuseppe Moscati
🇮🇹Avellino, AV, Italy
IRCCS Ospedale Oncologico Giovanni Paolo II
🇮🇹Bari, BA, Italy
Instituto Clinico Humanitas
🇮🇹Rozzano (MI), Lombardia, Italy
Azienda Ospedaliera di Perugia Santa Maria
🇮🇹Perugia, PG, Italy
U.O. di Oncologia Ospedale Villa Scassi
🇮🇹Genova, Italy
Universita Federico II UOC Oncologia Medica
🇮🇹Napoli, Italy
Azienda USL di Piacenza, Ospedale Gugliemimo Salieto
🇮🇹Piacenza, Italy
Azienda Ospedaliera S. Camillo-Forlanin
🇮🇹Rome, Italy
Hopital Jean Minjoz
🇫🇷Besancon Cedex, France
Marseille - Hopital Nord
🇫🇷Marseille, France
CH de la Region d'Annecy
🇫🇷Metz-Tessy, France
Centre Hospitalier Regional Hopital de la Source
🇫🇷Orleans, France
Fondation Hopital Saint Joseph
🇫🇷Paris, France
CHU de Rouen
🇫🇷Rouen, France
Fundacion Jimenez Diaz
🇪🇸Madrid, Spain
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
Complejo Asistencial Universitario de Leon
🇪🇸Leon, Spain
Hospital Son Llatzer
🇪🇸Palma de Mallorca, Spain
Kingston Health Sciences Centre
🇨🇦Kingston, Ontario, Canada
Odette Cancer Centre
🇨🇦Toronto, Ontario, Canada
Cetus Hospital Dia Oncologia
🇧🇷Belo Horizonte, Minas Gerais, Brazil
Henan province Cancer Hospital
🇨🇳Zhengzhou, Henan, China
Nanjing General Hospital
🇨🇳Nanjing, Jiangsu, China
Banner MD Anderson Cancer Center
🇺🇸Gilbert, Arizona, United States
National Jewish Health
🇺🇸Denver, Colorado, United States
H. Lee Moffitt Cancer Center
🇺🇸Tampa, Florida, United States
Hematology and Oncology Associates of NEPA
🇺🇸Dunmore, Pennsylvania, United States
Campbelltown Hospital
🇦🇺Campbelltown, New South Wales, Australia
The Reading Hospital Medical Center
🇺🇸West Reading, Pennsylvania, United States
Chris O'Brien Lifehouse
🇦🇺Camperdown, New South Wales, Australia
Nepean Hospital
🇦🇺Kingswood, New South Wales, Australia
Coffs Habour Health Campus - NCCI
🇦🇺Coffs Harbour, New South Wales, Australia
Gosford Hospital
🇦🇺Gosford, New South Wales, Australia
St. George Hospital, Cancer Care Centre
🇦🇺Kogarah, New South Wales, Australia
Liverpool Cancer Therapy Centre, Liverpool Hospital
🇦🇺Liverpool, New South Wales, Australia
Northern Cancer Institute St Leonards
🇦🇺St Leonards, New South Wales, Australia
Westmead Hospital
🇦🇺Westmead, New South Wales, Australia
Sunshine Coast University Hospital
🇦🇺Birtinya, Queensland, Australia
Princess Alexandra Hospital
🇦🇺Brisbane, Queensland, Australia
Monash Medical Centre
🇦🇺Clayton, Victoria, Australia
Mater Medical Centre
🇦🇺Brisbane, South, QLD, Australia
The Prince Charles Hospital
🇦🇺Chermside, Queensland, Australia
Royal Adelaide Hospital
🇦🇺Adelaide, South Australia, Australia
Royal Melbourne Hospital Research Foundation
🇦🇺Parkville, Victoria, Australia
Royal Hobart Hospital
🇦🇺Hobart, Tasmania, Australia
Austin Hospital
🇦🇺Heidelberg, Victoria, Australia
Epworth HealthCare - Richmond
🇦🇺Richmond, Victoria, Australia
Frankston Hospital - Peninsula Oncology Centre
🇦🇺Frankston, Victoria, Australia
Border Medical Oncology
🇦🇺Wodonga, Victoria, Australia
Fiona Stanley Hospital
🇦🇺Murdoch, Western Australia, Australia
Flinders Medical Center
🇦🇺Adelaide, Australia
St. Vincent's Hospital
🇦🇺Victoria Park, Australia
Hospital Evangelico de Cachoeiro de Itapemirim
🇧🇷Cachoeiro de Itapemirim, Espirito Santo, Brazil
Canberra Hospital
🇦🇺Garran, Australia
Suporte Nutricional e Quimioterapia LTDA PRONUTRIR
🇧🇷Fortaleza, Ceara, Brazil
Instituto Tacchini de Pesquisa em Saude
🇧🇷Bento Goncalves, Rio Grande Do Sul, Brazil
Clinica de Neoplasias Litoral
🇧🇷Itajai, Santa Catarina, Brazil
Centro de Oncologia e Radioterapia (COR) Mae de Deus
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Faculdade de Medicina do ABC
🇧🇷Sao Paulo, Santo Andre, Brazil
Fundacao Faculdade Regional de Medicina
🇧🇷Sao Jose do Rio Preto, Sao Paulo, Brazil
BCCA - Abbotsford Centre
🇨🇦Abbotsford, British Columbia, Canada
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada
BCCA - Vancouver Cancer Centre
🇨🇦Vancouver, British Columbia, Canada
The Moncton Hospital
🇨🇦Moncton, New Brunswick, Canada
Regional Health Authority B, Zone 2
🇨🇦Saint John, New Brunswick, Canada
Dr. H. Bliss Murphy Cancer Centre
🇨🇦St. John's, Newfoundland and Labrador, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
🇨🇦Hamilton, Ontario, Canada
London Regional Cancer Program
🇨🇦London, Ontario, Canada
Stronach Regional Health Centre at Southlake
🇨🇦Newmarket, Ontario, Canada
Niagara Health System
🇨🇦St. Catharines, Ontario, Canada
Health Sciences North
🇨🇦Sudbury, Ontario, Canada
Algoma District Cancer Program
🇨🇦Sault Ste. Marie, Ontario, Canada
Lakeridge Health Oshawa
🇨🇦Oshawa, Ontario, Canada
Ottawa Hospital Research Institute
🇨🇦Ottawa, Ontario, Canada
Humber River Hospital
🇨🇦Toronto, Ontario, Canada
Sinai Health System
🇨🇦Toronto, Ontario, Canada
PEI Cancer Treatment Centre
🇨🇦Charlottetown, Prince Edward Island, Canada
CHUM-Centre Hospitalier de l'Universite de Montreal
🇨🇦Montreal, Quebec, Canada
The Research Institute of the McGill University
🇨🇦Montreal, Quebec, Canada
University Institute of Cardiology and
🇨🇦Quebec City, Quebec, Canada
Centre Integre Universitaire De Sante Et De Services
🇨🇦Montreal, Quebec, Canada
Beijing Cancer Hospital
🇨🇳Beijing, Beijing, China
Saskatoon Cancer Centre
🇨🇦Saskatoon, Saskatchewan, Canada
Fujian Province Cancer Hospital
🇨🇳Fuzhou, Fujian, China
Guangdong General Hospital
🇨🇳Guangzhou, Guangdong, China
The People Hospital of Guangxi Zhuang Autonomous Reg
🇨🇳Nanning, Guangxi, China
The Second Xiangya Hospital of Central South Univer
🇨🇳Changsha, Hunan, China
Northern Jiangsu People Hospital
🇨🇳Yangzhou, Jiangsu, China
The Affiliated Hospital Of Qingdao University
🇨🇳Qingdao, Shandong, China
Sir run run shaw hospital School of Medicine
🇨🇳Hangzhou, Zhejiang, China
CRLCC - Paoli-Calmette
🇫🇷Marseille Cedex, BP, France
Hopital de la Croix-Rousse
🇫🇷Lyon, Cedex 04, France
Centre hospitalier universitaire de Montpellier
🇫🇷Montpellier, Cedex 05, France
AP-HP Hopital Tenon
🇫🇷Paris, Cedex 20, France
CHRU de Tours - Hopital Bretonneau
🇫🇷Tours Cedex, Tours Cedex 9, France
Bayonne - Centre Hospitalier
🇫🇷Bayonne, France
Polyclinique Bordeaux Nord
🇫🇷Bordeaux, France
Boulogne - Ambroise Pare
🇫🇷Boulogne, France
Caen - CHU
🇫🇷Caen, France
Centre Hospitalier de Chambery
🇫🇷Chambery, France
Centre Hospitalier de Cholet
🇫🇷Cholet, France
HIA Percy
🇫🇷Clamart, France
Clermont-Ferrand - CHU
🇫🇷Clermont-Ferrand, France
Hopital Louis Pasteur
🇫🇷Colmar, France
Annemasse - Centre Hospitalier Alpes Leman
🇫🇷Contamine Sur Arve, France
Centre Hospitalier Sud Francilien
🇫🇷Corbeil-Essonnes, France
Centre Hospitalier Intercommunal - Elbeuf
🇫🇷Elbeuf, France
Centre Hospitalier departemental
🇫🇷La Roche Sur Yon, France
CHU Hopital du Bocage
🇫🇷Dijon, France
Centre Hospitalier Lyon Sud
🇫🇷Lyon, France
Centre Hospitalier de Mulhouse
🇫🇷Mulhouse, France
Hopital Bichat
🇫🇷Paris, France
Centre Hospitalier de Perigueux
🇫🇷Perigueux, France
Centre Hospitalier de Saint-Quentin
🇫🇷Saint-Quentin, France
Institut de Cancerologie de la Loire
🇫🇷Saint-priest-en-jarez, France
Hopital Larrey
🇫🇷Toulouse, France
Villefranche sur Saone - CH
🇫🇷Villefranche Sur Saone, France
Fondazione Salvatore Maugeri Oncologia Medica
🇮🇹Pavia, PV, Italy
Centro di Riferimento Oncologico - CRO
🇮🇹Aviano, PN, Italy
OUC Oncologia Medica - Presidio Ospedaliero
🇮🇹Ravenna, RA, Italy
AOU Integrata Verona Policlinico GB
🇮🇹Verona, VR, Italy
U.O. di Oncologia Medica Azienda Ospedaliera G Rummo
🇮🇹Benevento, Italy
PO A Perrino ASL Brindisi - UOC Oncologia Medica
🇮🇹Brindisi, Italy
AOU Policlinico Vittorio Emanuele UOC di Oncologia
🇮🇹Catania, Italy
European Institute of Oncology
🇮🇹Milan, Italy
Azienda Ospedaliera di Rilievo Nazionale
🇮🇹Napoli, Italy
U.O.C. di Oncologia U.L.S.S. 13
🇮🇹Mirano, Italy
Unita Sperimentazioni Cliniche Istituto per lo
🇮🇹Napoli, Italy
Dott. Fortunato Ciardiello,Cattedra Oncologia Medica
🇮🇹Napoli, Italy
Japanese Red Cross Nagoya Daiichi Hospital
🇯🇵Nagoya, Aichi, Japan
National Hospital Organization Shikoku Cancer Center
🇯🇵Matsuyama-shi, Ehime, Japan
UOC Oncologia Medica II Instituto Oncologio Veneto
🇮🇹Padova, Italy
Nagoya University Hospital
🇯🇵Nagoya, Aichi, Japan
National Cancer Center Hospital East
🇯🇵Kashiwa, Chiba, Japan
Gifu Univiesity Hospital
🇯🇵Gifu-shi, Gifu, Japan
Gunma University Hospital
🇯🇵Maebashi-shi, Gunma, Japan
Hospital of the University of Occupational and
🇯🇵Kitakyushu, Fukuoka, Japan
Koube University Hospital
🇯🇵Kobe-shi, Hyogo, Japan
Sendai Kousei Hospital
🇯🇵Sendai, Miyagi, Japan
Kurashiki Central Hospital
🇯🇵Kurashiki, Okayama, Japan
Kanazawa University Hospital
🇯🇵Kanazawa, Ishikawa, Japan
Kinki University Hospital Faculty of Medicine
🇯🇵Osaka-Sayama, Osaka, Japan
Tottori University Hospital
🇯🇵Yonago, Tottori, Japan
National Hospital Organization Kinki-Chuo
🇯🇵Sakai, Osaka, Japan
Chiba University Hospital
🇯🇵Chiba, Japan
National Hospital Organization Yamaguchi
🇯🇵Ube, Yamaguchi, Japan
Kyushu University Hospital
🇯🇵Fukuoka, Japan
Hiroshima City Hiroshima Citizens Hospital
🇯🇵Hiroshima, Japan
Hiroshima University Hospital
🇯🇵Hiroshima, Japan
Juntendo University Hospital
🇯🇵Tokyo, Japan
Tokyo Medical University Hospital
🇯🇵Tokyo, Japan
Chungbuk National University Hospital
🇰🇷Cheongju, Chungcheongbuk Do, Korea, Republic of
Keimyung University Dongsan Medical Center
🇰🇷Daegu, Dalseogu, Korea, Republic of
Veterans Health Service Medical Center
🇰🇷Seoul, Gangdong-gu, Korea, Republic of
Chung Ang University Hospital
🇰🇷Seoul, Dongjak Gu, Korea, Republic of
Ajou University Hospital
🇰🇷Suwon, Gyeonggi Do, Korea, Republic of
Kangbuk Samsung Hospital
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea Bucheon
🇰🇷Bucheon, Gyeonggi Do, Korea, Republic of
The Catholic University of Korea,
🇰🇷Seoul, Korea, Republic of
Tergooi locatie Hilversum
🇳🇱Hilversum, Noord Holland, Netherlands
Isala
🇳🇱Zwolle, Overijssel, Netherlands
Amphia ziekenhuis
🇳🇱Breda, Noord Brabant, Netherlands
Netherlands Cancer Institute
🇳🇱Amsterdam, Netherlands
UMC Groningen
🇳🇱Groningen, Netherlands
Erasmus Medical Center (EMC)
🇳🇱Rotterdam, Netherlands
Academical Hospital Maastricht
🇳🇱Maastricht, Netherlands
Christchurch Hospital
🇳🇿Christchurch, New Zealand
Klinika Onkologii i Radioterapii Uniwersyteckie
🇵🇱Gdansk, Poland
Specjalistyczny Szpital im
🇵🇱Szczecin, Poland
Spitalul de Psihiatrie Dr. Constantin Gorgos
🇷🇴Bucharest, Romania
OCH - Ovidius Clinical Hospital
🇷🇴Constanta, Romania
Hoapital Quiron Dexeus
🇪🇸Barcelona, Spain
Hospital General Universitario de Valencia
🇪🇸Valencia, Spain
Hospital Universitario de Salamanca
🇪🇸Salamanca, Spain
Far Eastern Memorial Hospital
🇨🇳New Taipei City;, Taiwan;, Taiwan
Chang-Gung Memorial Hospital - Kaohsiung
🇨🇳Kaohsiung, Taiwan
Kaohsiung Medical University
🇨🇳Kaohsiung, Taiwan
China Medical University Hospital
🇨🇳Taichung, Taiwan
Dnipropetrovsk City Clinical Hospital No.4
🇺🇦Dnipropetrovsk, Ukraine
University of Florida
🇺🇸Gainesville, Florida, United States
Thomas Jefferson University
🇺🇸Philadelphia, Pennsylvania, United States